Moleculin nearing pivotal AML trial data readout, unblinding expected before June 30

Moleculin Biotech announced it is approaching a critical milestone: the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial. This trial evaluates Annamycin, the company's lead drug candidate, combined with cytarabine for treating acute myeloid leukemia patients who have relapsed or not responded to initial therapy.

The study tests two different Annamycin doses against a control arm, and results are expected before the end of June 2026. For retail investors, this is a binary event that will likely drive significant stock movement. Positive data could validate Annamycin's efficacy and advance the drug toward potential FDA approval in a serious cancer indication. Negative or inconclusive results could derail the program.

The company is reaffirming its previously communicated timeline, suggesting the trial remains on track. Investors should watch for the actual data release in the coming weeks and pay attention to key metrics like response rates and safety profiles compared to the control arm.